1-13 of 13
Yelena Y. Janjigian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer

Available to Purchase
Henry S. Walch, Raktim Borpatragohain, Justin Jee, Waleed Chatila, Christopher Fong, Steven B. Maron, Geoffrey Y. Ku, David H. Ilson, Yelena Y. Janjigian, Abraham J. Wu, Pari Shah, Daniel G. Coit, Manjit S. Bains, Valerie W. Rusch, Bernard J. Park, Matthew J. Bott, Katherine Gray, David R. Jones, Michael Berger, Nikolaus Schultz, Vivian E. Strong, Daniela Molena, Smita Sihag
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (10): 1912–1921.
https://doi.org/10.1158/1078-0432.CCR-24-3473
Published: 15 May 2025
View articletitled, Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer
Open the PDF for Clinical Implications of The Cancer Genome Atlas Molecular Classification System in Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Free
Changhwan Yoon, Do Joong Park, Benjamin Schmidt, Nicholas J. Thomas, Hae-June Lee, Teresa S. Kim, Yelena Y. Janjigian, Deirdre J. Cohen, Sam S. Yoon
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4803.
https://doi.org/10.1158/1078-0432.CCR-24-2134
Published: 15 October 2024
View articletitled, Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Open the PDF for Retraction: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance in another window
Journal Articles

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

Open Access
Steven B. Maron, Walid Chatila, Henry Walch, Joanne F. Chou, Nicholas Ceglia, Ryan Ptashkin, Richard Kinh Gian Do, Viktoriya Paroder, Neeta Pandit-Taskar, Jason S. Lewis, Tiago Biachi De Castria, Shalom Sabwa, Fiona Socolow, Lara Feder, Jasmine Thomas, Isabell Schulze, Kwanghee Kim, Arijh Elzein, Viktoria Bojilova, Matthew Zatzman, Umesh Bhanot, Rebecca J. Nagy, Jeeyun Lee, Marc Simmons, Michal Segal, Geoffrey Yuyat Ku, David H. Ilson, Marinela Capanu, Jaclyn F. Hechtman, Taha Merghoub, Sohrab Shah, Nikolaus Schultz, David B. Solit, Yelena Y. Janjigian
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3633–3640.
https://doi.org/10.1158/1078-0432.CCR-22-3769
Published: 15 September 2023
View articletitled, Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Open the PDF for Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting

Available to Purchase
Zev A. Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y. Janjigian, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1360–1367.
https://doi.org/10.1158/1078-0432.CCR-22-2920
Published: 03 April 2023
View articletitled, Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
Open the PDF for Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting in another window
Includes: Supplementary data
Journal Articles

The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma

Available to Purchase
Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Sergio De La Torre, Yelena Y. Janjigian, Steven B. Maron, Geoffrey Y. Ku, Laura H. Tang, Pari M. Shah, Abraham Wu, David R. Jones, David B. Solit, Nikolaus Schultz, Karuna Ganesh, Michael F. Berger, Daniela Molena
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2669–2678.
https://doi.org/10.1158/1078-0432.CCR-21-4016
Published: 13 June 2022
View articletitled, The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma
Open the PDF for The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways

Available to Purchase
Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Francisco Sanchez-Vega, Walid K. Chatila, Sergio A. De La Torre, Assem Patel, Yelena Y. Janjigian, Steven Maron, Geoffrey Y. Ku, Laura H. Tang, Jaclyn Hechtman, Pari M. Shah, Abraham J. Wu, David R. Jones, Daniela Molena, David B. Solit, Nikolaus Schultz, Michael F. Berger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3491–3498.
https://doi.org/10.1158/1078-0432.CCR-20-4707
Published: 15 June 2021
View articletitled, Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Open the PDF for Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways in another window
Includes: Supplementary data
Journal Articles

Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer

Free
Megan Greally, Joanne F. Chou, Walid K. Chatila, Matthew Margolis, Marinela Capanu, Jaclyn F. Hechtman, Yaelle Tuvy, Ritika Kundra, Foysal Daian, Marc Ladanyi, David P. Kelsen, David H. Ilson, Michael F. Berger, Laura H. Tang, David B. Solit, Luis A. Diaz, Jr, Nikolaus Schultz, Yelena Y. Janjigian, Geoffrey Y. Ku
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6160–6169.
https://doi.org/10.1158/1078-0432.CCR-18-3603
Published: 15 October 2019
View articletitled, Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Open the PDF for Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer

Free
Elizabeth Won, Azfar Basunia, Walid K. Chatila, Jaclyn F. Hechtman, Joanne F. Chou, Geoffrey Y. Ku, Sree B. Chalasani, Michelle S. Boyar, Zoe Goldberg, Avni M. Desai, Yaelle Tuvy, Michael F. Berger, Laura Tang, David P. Kelsen, Mark Schattner, David H. Ilson, Marinela Capanu, David B. Solit, Nikolaus Schultz, Yelena Y. Janjigian
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3811–3817.
https://doi.org/10.1158/1078-0432.CCR-18-3789
Published: 01 July 2019
View articletitled, Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer
Open the PDF for Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

Free
James J. Harding, Subhiksha Nandakumar, Joshua Armenia, Danny N. Khalil, Melanie Albano, Michele Ly, Jinru Shia, Jaclyn F. Hechtman, Ritika Kundra, Imane El Dika, Richard K. Do, Yichao Sun, T. Peter Kingham, Michael I. D'Angelica, Michael F. Berger, David M. Hyman, William Jarnagin, David S. Klimstra, Yelena Y. Janjigian, David B. Solit, Nikolaus Schultz, Ghassan K. Abou-Alfa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2116–2126.
https://doi.org/10.1158/1078-0432.CCR-18-2293
Published: 01 April 2019
View articletitled, Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
Open the PDF for Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies in another window
Includes: Supplementary data
Journal Articles

RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance

Free
Changhwan Yoon, Do Joong Park, Benjamin Schmidt, Nicholas J. Thomas, Hae-June Lee, Teresa S. Kim, Yelena Y. Janjigian, Deirdre J. Cohen, Sam S. Yoon
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 3974–3988.
https://doi.org/10.1158/1078-0432.CCR-14-0011
Published: 01 August 2014
View articletitled, RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance
Open the PDF for RETRACTED: CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance in another window
Includes: Supplementary data
Journal Articles

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

Free
Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (19): 6322–6328.
https://doi.org/10.1158/1078-0432.CCR-11-1080
Published: 02 October 2011
View articletitled, Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib
Open the PDF for Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib in another window
Includes: Supplementary data
Journal Articles

Molecular Classification of Gastric Cancer: A New Paradigm

Free
Manish A. Shah, Raya Khanin, Laura Tang, Yelena Y. Janjigian, David S. Klimstra, Hans Gerdes, David P. Kelsen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2693–2701.
https://doi.org/10.1158/1078-0432.CCR-10-2203
Published: 01 May 2011
View articletitled, Molecular Classification of Gastric Cancer: A New Paradigm
Open the PDF for Molecular Classification of Gastric Cancer: A New Paradigm in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

Free
Yelena Y. Janjigian, Christopher G. Azzoli, Lee M. Krug, Leanne K. Pereira, Naiyer A. Rizvi, M Catherine Pietanza, Mark G. Kris, Michelle S. Ginsberg, William Pao, Vincent A. Miller, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2521–2527.
https://doi.org/10.1158/1078-0432.CCR-10-2662
Published: 14 April 2011
View articletitled, Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib
Open the PDF for Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib in another window